Milk thistle reduces chemotherapy-induced liver toxicity, study says

According to research published online in the journal Cancer, the herb milk thistle may provide cancer patients undergoing chemotherapy with much-needed liver protection.

One of the many toxic effects of chemotherapy occurs in the liver; chemo drugs can cause liver inflammation, a serious enough side effect to force doctors to either lower chemotherapy doses or stop the treatment altogether, compromising the patient's cancer care.

Liver inflammation is measured by examining liver enzymes in blood levels, specifically the enzymes aspartate amino transferase (AST) and amino alanine transferase (ALT).

The new randomized, controlled, double blind study—carried out by Kara Kelly, MD and colleagues of the New York-Presbyterian Hospital/Columbia University Medical Center’s Herbert Irving Comprehensive Cancer Center in New York City—examined children with acute lymphoblastic leukemia (ALL). Results showed that the patients who received milk thistle showed substantially lower blood levels of both AST and, to a lesser extent, ALT.

Furthermore, milk thistle did not interfere with the anti-cancer mechanisms of the chemotherapy itself.

By Ross Bonander

Source: E Ladas et al. A randomized, controlled, double blind pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer; Published Online: December 14, 2009 (DOI: 10.1002/cncr.24723).

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap